Home Trials Current Trials

ASTN Current Trials

AFFINITY: Assessment of fluoxetine in stroke recovery trial

E-mail Print PDF

Lead PI:  Dr Graeme J Hankey and Associate Professor Maree L. Hackett

Status: Recruiting

No. of Patients Currently Recruited: 246                                No. of Patients Required:  1600

An Australian-lead investigator initiated, multi-centre, prospective, randomized, parallel group, double blind placebo-controlled trial to establish the effect(s) of routine administration of fluoxetine (20mg once daily) for 6 months in patients with recent stroke on functional outcome at 6 months and one year.

Trial URL:

ANZCTR No: ACTRN12611000774921



Last Updated ( Wednesday, 06 July 2016 15:11 )

COMPARE: Participant Information for People With Aphasia Constraint Induced or Multi-Modal aphasia rehabilitation: A Randomised Controlled Trial (RCT) for stroke related chronic aphasia

E-mail Print PDF

Lead PI: Associate Professor Miranda Rose

Status: Recruiting

No. of Patients Currently Recruited: 1                                No. of Patients Required:  216

COMPARE is a randomized controlled trial of 216 participants comparing Constraint Induced Aphasia Therapy and Multi-modality Aphasia Therapy to usual care for people with aphasia 6 months to 15 years following stroke. Primary outcome is aphasia severity immediately following treatment plus secondary outcomes at 3 months post treatment. An economic analysis will occur.

Trial URL:

ANZCTR No: ACTRN126125000618550





Last Updated ( Wednesday, 06 July 2016 14:49 )

IMS III: Interventional Management of Stroke Trial

E-mail Print PDF
Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV Rt-PA (Activase®) Alone When Initiated Within Three Hours of Acute Ischemic Stroke Onset. IV rt-PA is an effective therapy for acute ischemic stroke but has substantial limitations when used alone to open blocked arteries The Interventional Management of Stroke (IMS III) Trial is a multi-center study that will compare two different treatment approaches for restoring blood flow to the brain. One approach, giving the clot-dissolving drug rt-PA, is already FDA-approved when given through a vein (IV). This treatment will be compared to a new approach, giving rt-PA at a lower dose first through IV in the arm and then, if a blood clot in the brain artery is found, through a small tube or catheter at the site of the blood clot (intra-arterial or IA) to see which is better. Both approaches must be initiated within three hours of stroke onset.

A total of 900 participants shall be recruited
Last Updated ( Tuesday, 25 August 2015 13:13 )

Intra-arterial Plasmin Study

E-mail Print PDF

Intra-arterial Plasmin Study

A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke.
Phase 1/2a, open-label, multi-center, sequential dose escalation, safety study of Plasmin (Human) in acute ischemic stroke caused by middle cerebral artery occlusion documented by arteriography. Plasmin (Human) will be administered through a catheter into the thrombus within 9 hours of stroke onset. A maximum of seventy-five (75) patients will receive Plasmin (Human), a maximum of twenty-five (25) patients at each of the 3 dose levels (20 mg, 40 mg, and 60 mg). The objectives of this study are to determine the safety and tolerability of Plasmin (Human), to select a dose for further testing, and to determine the proportion of patients with partial or full recanalization.

A total of 75 participants shall be recruited. 


Last Updated ( Tuesday, 25 August 2015 13:14 )
Page 2 of 3

ASTN Latest news

Top Views